A new drug that appears to improve learning and memory in animals and may reduce the accumulation of destructive plaque that is the hallmark of Alzheimer’s disease is under study at the Medical College of Georgia.   MCG is enrolling Alzheimer’s patients with mild to moderate memory loss in a 12-week study that compares different doses of the drug – still known only by a number – to placebo. ; The study is being conducted at approximately 40 sites worldwide, including 34 sites in the United States.   “We want to see if this drug will improve cognition or memory in Alzheimer’s disease,” said Dr. Jeffrey L. Rausch, psychiatrist, vice chair of the MCG Department of Psychiatry and Health Behavior and a principal investigator on the study.   The drug, developed by Sanofi-Synthelabo, Inc., in France, has been shown in published studies to improve episodic memory (using an object recognition task) and to reverse learning decline in aging rats, Dr.Rausch said.   Previous clinical trials have suggested the drug is safe in humans; the current study will look at its efficacy and safety.   The drug is among the first to target 5HT4 receptors, one of the numerous receptors that

Ce contenu est restreint aux membres. Si vous êtes un utilisateur enregistré, connectez vous. Les nouveaux utilisateurs peuvent s'enregistrer ci-dessous.

Connexion pour les Utilisateurs enregistrés
   
Nouvel Utilisateur?
*Champ requis